3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Turcot syndrome
1
Pancreatic Neoplasms
1
Melanoma
1
Advanced Pancreatic Cancer
1
Interventions
Nivolumab
5
pembrolizumab
3
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
durvalumab
2
atezolizumab
2
Celecoxib
2
spartalizumab
1
relatlimab
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
danvatirsen
1
XELOX
1
Surgical Procedures, Operative
1
Oxaliplatin
1
Leucovorin
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
IMM-101
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
DEAE-Dextran
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Turcot syndrome
×
IMM-101
×
Clear all
NCT05118724
2025-06-15
ANTONIO
AIO-Studien-gGmbH
Phase 2
Active not recruiting
80 enrolled